COVID-19重症幸存者一年死亡率和再入院率:一项基于人群的队列研究
该研究为加拿大安大略省基于人群的回顾性观察性队列研究,纳入102个中心共6098例因COVID-19入住ICU并存活出院的成人患者,与非COVID-19肺炎重症幸存者(n=2568)比较。采用重叠倾向评分加权和病因特异性比例风险模型分析。结果显示,COVID-19组1年内急诊就诊(HR 0.65,95%CI 0.60-0.71)、再入院(HR 0.56,95%CI 0.51-0.62)、ICU再入院(HR 0.44,95%CI 0.37-0.53)和死亡(HR 0.67,95%CI 0.58-0.78)风险均更低。提示COVID-19重症幸存者出院后医疗资源使用和死亡风险低于非COVID-19肺炎重症幸存者。
要点
- COVID-19重症幸存者1年死亡风险低于非COVID-19肺炎重症幸存者(HR 0.67,95%CI 0.58-0.78)。
- COVID-19重症幸存者1年再入院风险更低(HR 0.56,95%CI 0.51-0.62)。
- COVID-19重症幸存者1年ICU再入院风险更低(HR 0.44,95%CI 0.37-0.53)。
- COVID-19重症幸存者1年急诊就诊风险更低(HR 0.65,95%CI 0.60-0.71)。
- 总体队列中,26.4%再入院、6.1%ICU再入院、15.0%在1年内死亡。
适用人群与场景
- 加拿大安大略省102个中心收治的成人(≥18岁)COVID-19重症幸存者,于2020年1月1日至2022年3月31日入住ICU并存活出院,共6098例。
- 对照为非COVID-19肺炎重症幸存者,共2568例。
研究设计与关键结果
- 研究类型:基于人群的回顾性观察性队列研究,纳入102个中心,COVID-19组6098例,非COVID-19肺炎对照组2568例。
- 平均年龄59.6岁,女性占38.5%。
- COVID-19组中1610例(26.4%)再入院,375例(6.1%)ICU再入院,917例(15.0%)在1年内死亡。
- 与非COVID-19肺炎重症幸存者相比,COVID-19重症幸存者1年内急诊就诊风险更低(HR 0.65,95%CI 0.60-0.71)。
- 与非COVID-19肺炎重症幸存者相比,COVID-19重症幸存者1年内再入院风险更低(HR 0.56,95%CI 0.51-0.62)。
- 与非COVID-19肺炎重症幸存者相比,COVID-19重症幸存者1年内ICU再入院风险更低(HR 0.44,95%CI 0.37-0.53)。
- 与非COVID-19肺炎重症幸存者相比,COVID-19重症幸存者1年内死亡风险更低(HR 0.67,95%CI 0.58-0.78)。
- 采用重叠倾向评分加权和病因特异性比例风险模型进行比较。
证据类型、等级与局限
- 证据类型:基于人群的回顾性观察性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate 1-year outcomes (mortality, and recurrent hospital and ICU readmission) in adult survivors of COVID-19 critical illness compared with survivors of critical illness from non-COVID-19 pneumonia.
DESIGN: Population-based retrospective observational cohort study.
SETTING: Province of Ontario, Canada.
PATIENTS: Six thousand ninety-eight consecutive adult patients (≥ 18 yr old) from 102 centers, admitted to ICU with COVID-19 (from January 1, 2020, to March 31, 2022), and surviving to hospital discharge.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: The primary outcome was 1-year mortality. We also evaluated the number of emergency department (ED) visits, hospital readmissions, and ICU readmissions over this same time period. We compared patients using overlap propensity score-weighted, cause-specific proportional hazard models. Mean age was 59.6 years and 38.5% were female. Of these patients, 1610 (26.4%) and 375 (6.1%) were readmitted to hospital and ICU, respectively, and 917 (15.0%) died within 1 year. Compared with survivors of critical illness from non-COVID-19 pneumonia ( n = 2568), those who survived COVID-19 critical illness had a lower risk of ED visit (hazard ratio [HR], 0.65 [95% CI, 0.60-0.71]), hospital readmission (HR, 0.56 [95% CI, 0.51-0.62]), ICU readmission (HR, 0.44 [95% CI, 0.37-0.53]), and mortality (HR, 0.67 [95% CI, 0.58-0.78]) within 1 year.
CONCLUSIONS: Risk of ED visit, hospital readmission, ICU readmission, and mortality within 1 year of discharge among survivors of COVID-19 critical illness was lower than survivors of critical illness from non-COVID-19 pneumonia.
参考来源
- Fernando SM, Qureshi D, Ante Z, et al. One-Year Mortality and Hospital Readmission in Survivors of COVID-19 Critical Illness-A Population-Based Cohort Study. Crit Care Med. 2025. PMID: 40013851. doi:10.1097/CCM.0000000000006603
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。